VectorXcellerator: OXB has selected the first programmes to move forward through VectorXcellerator, supporting earlier collaboration in advanced therapies.

OXB launches fast-track offering for AAV and lentiviral vector platforms, accelerating viral vector development and manufacture.

News

Half Year Trading Update and Notice of Results

7 August, 2026 | Press Release

View details >
Press Release

OXB Selected as GMP Manufacturing Partner to Support Manufacturing of Plowshare Therapies’ AAV Gene Therapy Programme

16 July, 2026 | Press Release

View details >
Press Release

OXB Capital Markets Event

2 June, 2026 | Press Release

View details >
Press Release

OXB to exhibit and present at the 30th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

8 May, 2026 | Press Release

View details >
Press Release

OXB launches fast-track offering for AAV and lentiviral vector platforms, accelerating viral vector development and manufacture

13 April, 2026 | Press Release

View details >
Press Release

OXB recognised as ‘Most Innovative CDMO (Cell & Gene)’ at 2026 CDMO Leadership Awards

27 March, 2026 | Press Release

View details >
Press Release

Preliminary results for the year ended 31 December 2025

26 March, 2026 | Press Release

View details >
Press Release

OXB enters into licensing agreement with Viral Vector Manufacturing Facility (VVMF), providing access to its AAV and LV viral vector platforms

18 March, 2026 | Press Release

View details >
Press Release

OXB announces date for Capital Markets Day and participation in upcoming investor conferences

3 March, 2026 | Press Release

View details >
Press Release
OXB-News-1-832x480px
OXB-News-4-832x480px
OXB-News-2-832x480px